Samsung Biologics Profit Improves Yet Stock Undervalued: Why Samsung Biologics is rated Buy as strong margins and revenue growth persist despite labor disruption fears, leaving the stock below the average analyst target. 2026년 07월 07일 English
Samsung Biologics Earnings Jump 25.8% YoY: Key Risks Samsung Biologics is rated Buy with strong growth and margins, but stock risk is driven by labor and legal disputes that could disrupt production, raise costs, and hurt future earnings. 2026년 06월 11일 English
SoFi Technologies Inc Stock Holds Near 19: What To Watch SoFi is a Hold: revenue up 39.6% YoY but net income down 47.8%; bank charter hopes and upcoming earnings may help, yet profitability proof is missing. 2026년 04월 17일 English
